Safety and efficacy of anti‐tachycardia pacing in patients with hypertrophic cardiomyopathy implanted with an ICD

• Published in: Pacing and clinical electrophysiology Vol. 42; no. 6; pp. 610 - 616
• Main Authors: Adduci, Carmen, Semprini, Lorenzo, Palano, Francesca, Musumeci, Maria Beatrice, Volpe, Massimo, Autore, Camillo, Francia, Pietro
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.06.2019
• Subjects: antitachycardia pacing; Arrhythmia; Cardiac arrhythmia; Cardiomyopathy; Cardiomyopathy, Hypertrophic - complications; Defibrillators; Defibrillators, Implantable; Degeneration; Female; Fibrillation; Humans; hypertrophic cardiomyopathy; implantable cardioverter defibrillator; Male; Middle Aged; Patients; Primary Prevention; Retrospective Studies; Risk Assessment; Secondary Prevention; Tachycardia; Tachycardia, Ventricular - prevention & control; Ventricle; ventricular arrhythmia; ventricular arrhythmia; implantable cardioverter defibrillator; hypertrophic cardiomyopathy; antitachycardia pacing
• ISSN: 0147-8389; 1540-8159
• DOI: 10.1111/pace.13665

Background In hypertrophic cardiomyopathy (HCM) patients implanted with an implantable cardioverter defibrillator (ICD), clinical outcomes of antitachycardia pacing (ATP) have been poorly explored. In a retrospective analysis of a cohort of consecutive HCM patients implanted with an ICD, we aimed to assess the efficacy, safety, and clinical value of ATP. Methods The cohort of HCM patients implanted with a transvenous ICD and followed in our center was assessed for device intervention from implantation to last clinical follow‐up. Results Overall 77 patients (45 males; mean age: 46 ± 16 years) were analyzed. After 67 ± 41 months, 24 patients had 49 ventricular tachycardia/fibrillation (VT/VF) appropriately treated (5.8% per year). Among 39 monomorphic VTs, ATP was effective in 27 (success rate: 69%). Mean time from VT onset to ATP delivery was 9.1 ± 4.9 s. The only clinical variable improving ATP success was use of beta‐blockers (81% vs 50%; P = .04). Out of 12 ineffectively treated VTs, one was immediately shocked, four self‐terminated after 18 ± 12 s, and seven (18%) were accelerated to a new VT. ATP was also delivered for 27 of 42 inappropriately detected episodes and induced two de novo VTs (7%). In the per patient analysis, 14 out 77 (18%) patients had one or more appropriate and effective ATP (3.4% per year), and only six (8%; 1.4% per year) received more than one ATP. Conclusion ATP is moderately effective for the treatment of monomorphic VTs in HCM patients. However, the rate of appropriate ATP therapies is low, ATP is often prematurely delivered, and ATP‐induced arrhythmia degeneration is of concern.